



Polyglucosan body structure in Lafora disease

M. Kathryn Brewer, Jean-Luc Putaux, Alberto Rondon, Annette Uittenbogaard, Mitchell Sullivan, Matthew Gentry

► To cite this version:

M. Kathryn Brewer, Jean-Luc Putaux, Alberto Rondon, Annette Uittenbogaard, Mitchell Sullivan, et al.. Polyglucosan body structure in Lafora disease. Carbohydrate Polymers, 2020, 240, pp.116260. 10.1016/j.carbpol.2020.116260 . hal-02570792

HAL Id: hal-02570792

<https://hal.science/hal-02570792>

Submitted on 10 Nov 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

Title: Polyglucosan body structure in Lafora disease

Keywords (up to 10): glycogen; starch; epilepsy; polyglucosan bodies; Lafora bodies;
Lafora disease; glycogen storage disease

Authors: M. Kathryn Brewer^{1,2,3}, Jean-Luc Putaux⁴, Alberto Rondon¹, Annette
Uittenbogaard¹, Mitchell A. Sullivan⁵, Matthew S. Gentry^{1,2}.

Affiliations:

¹ Department of Molecular and Cellular Biochemistry, University of Kentucky College of
Medicine, Lexington, KY 40536, USA.

² Lafora Epilepsy Cure Initiative, Epilepsy and Brain Metabolism Center, and Center for
Structural Biology, University of Kentucky College of Medicine, Lexington, KY 40536,
USA.

³ Institute for Research in Biomedicine (IRB Barcelona), 08028 Barcelona, Spain.

⁴ Univ. Grenoble Alpes, CNRS, CERMAV, F-38000 Grenoble, France.

⁵ Glycation and Diabetes Group, Mater Research Institute-The University of Queensland,
Translational Research Institute, Woolloongabba, Queensland, Australia.

Correspondence: Matthew S. Gentry, Department of Molecular and Cellular Biochemistry,
University of Kentucky College of Medicine, Lexington, KY 40536, USA.
Phone: +1 859 323 8482; Fax: +1 859 323 5505; Email: matthew.gentry@uky.edu

26 **Abbreviations**

27 PGB: polyglucosan body; LD: Lafora disease; LB: Lafora body; GSD: glycogen storage
28 disease; CLD: chain length distribution; TEM: transmission electron microscopy; WAXS:
29 wide-angle X-ray scattering; SAXS: small-angle X-ray scattering; DIC: differential
30 interference contrast; SmLBs: skeletal muscle LBs; BrLBs: brain LBs; HtLBs: heart LBs;
31 PAPS: potato amylopectin starch; SEC: size exclusion chromatography; R_h : hydrodynamic
32 radius; WT: wild-type.

33

Abstract (150 words or less)

Abnormal carbohydrate structures known as polyglucosan bodies (PGBs) are associated with neurodegenerative disorders, glycogen storage diseases (GSDs), and aging. A hallmark of the GSD Lafora disease (LD), a fatal childhood epilepsy caused by recessive mutations in the *EPM2A* or *EPM2B* genes, are cytoplasmic PGBs known as Lafora bodies (LBs). LBs result from aberrant glycogen metabolism and drive disease progression. They are abundant in brain, muscle and heart of LD patients and *Epm2a*^{-/-} and *Epm2b*^{-/-} mice. LBs and PGBs are histologically reminiscent of starch, semicrystalline carbohydrates synthesized for glucose storage in plants. In this study, we define LB architecture, tissue-specific differences, and dynamics. We propose a model for how small polyglucosans aggregate to form LBs. LBs are very similar to PGBs of aging and other neurological disorders, and so these studies have direct relevance to the general understanding of PGB structure and formation.

1. Introduction

Polyglucosan bodies (PGBs) are a common feature of glycogen storage diseases (GSDs), neurodegenerative diseases, and physiological aging (Cavanagh, 1999; Duran & Guinovart, 2015; Rohn, 2015). PGBs range in size from 2 to 50 μm in diameter and, unlike the proteinaceous inclusion bodies of neurodegenerative diseases, they are primarily made of an aberrant glucose polymer called polyglucosan (Raben et al., 2001). These glucose polymers are considered “aberrant” because they differ significantly in structure and appearance from the normal glucose polymers of mammalian tissues, namely glycogen. Subtle chemical and ultrastructural differences distinguish the PGBs of various pathologies (Cavanagh, 1999). What unites them is their chemical resemblance to mammalian glycogen and plant starch, the two major forms of glucose storage in living organisms (Emanuelle, Brewer, Meekins, & Gentry, 2016).

Glycogen is a polysaccharide comprised of α -1,4-linked linear chains of glucose with α -1,6-linked branches. Starch contains two types of polysaccharides, amylopectin and amylose. Amylopectin is the major component of starch and, like glycogen, contains both α -1,4 and α -1,6-linkages. Amylose, the minor constituent of starch (typically 15-30% of total starch weight), is comprised almost exclusively of linear α -1,4-linked chains with few branch points. Although glycogen and amylopectin have identical glycosidic bonding, differences in chain length and branching frequency give them distinct properties. The linear chains of glycogen have approximately 13 glucose units and two branch points, making glycogen a water-soluble, continuously branched macromolecule that is designed for rapid glucose release (Melendez-Hevia, Waddell, & Shelton, 1993; Roach, Depaoli-Roach, Hurley, & Tagliabracci, 2012). In contrast, the linear glucose chains of amylopectin contain on average 20-30 glucose units and branch points are clustered, although the arrangement of the clusters is still under investigation (Bertoft, 2017; Jane et al., 1999). The long, linear regions of the

glucan chains intertwine to form double helices, producing crystalline layers (called lamellae) interleaved with more hydrated, amorphous regions containing the branch points. The crystalline and amorphous lamellae radiate from a central origin, and as a result, starch granules are a densely packed, semicrystalline glucose cache that can reach up to 100 μm in diameter in some plant tissues (Emanuelle et al., 2016; Lourdin et al., 2015). Amylose is interspersed among the amylopectin chains (Bertoft, 2017). Starch and glycogen both contain covalently bound phosphate, located at the 3- and 6-hydroxyls in amylopectin and 2-, 3-, and 6-hydroxyls in glycogen (DePaoli-Roach et al., 2014; Nitschke et al., 2013; Ritte et al., 2006; Young et al., 2019). Amylopectin contains higher levels of phosphate than glycogen: 0.1-0.5% versus 0.064-0.25% by weight, depending on the plant or tissue source (Gentry, Dixon, & Worby, 2009).

Starch-like structures in the brains of elderly patients were first described in 1836 by J. E. Purkinje, who named them *corpora amylacea* (Latin for "starch-like bodies"). In 1854, Rudolf Virchow observed a substance in the diseased nervous system that stained with iodine in a manner similar to plant starch, coining the term "amyloid" (Virchow, 1854). Subsequently, others also described "amyloid" deposits that were later discovered to be proteinaceous, so the term now typically refers to the inclusions of Alzheimer's and other amyloidoses (Kyle, 2001; Sipe & Cohen, 2000). But *corpora amylacea* and PGBs are, in fact, true amyloid: in addition to their similarity in size and shape and staining characteristics to starch, they are comprised primarily of insoluble glucose polymers with chain lengths longer than normal glycogen (Cafferty et al., 1991; Cavanagh, 1999; Sakai, Austin, Witmer, & Trueb, 1969). In some cases, these PGBs also contain elevated phosphate (Sullivan et al., 2019). Since glycogen synthase is the only known enzyme able to catalyze glucose polymerization *in vivo* in mammals, PGBs are considered a pathological result of aberrant glycogen metabolism (Duran & Guinovart, 2015; Raben et al., 2001; Roach et al., 2012).

Lafora disease (LD) is a progressive myoclonus epilepsy and a GSD (OMIM: 254780) that manifests during the teen years and leads to early death (Akman, Oldfors, & DiMauro, 2015; Gentry et al., 2020; Gentry, Guinovart, Minassian, Roach, & Serratos, 2018; Minassian, 2001). LD is characterized by cytoplasmic PGBs known as Lafora bodies (LBs) that are found in neurons, astrocytes, skeletal and cardiac myocytes, and other cell types (Augé, Pelegrí, et al., 2018; Criado et al., 2012; Rubio-Villena et al., 2018; Van Heycop Ten Ham, 1975). Like other PGBs, LBs from human tissues were described as starch-like in the early- and mid-1900s based on their chemical and structural characteristics (Lafora, 1911; Yokoi, Austin, Witmer, & Sakai, 1968). Recessive mutations in either of the *Epilepsy, progressive myoclonus 2* genes (*EPM2A* or *EPM2B*) cause LD in humans, and *Epm2a*^{-/-} and *Epm2b*^{-/-} mice recapitulate the disease with LB accumulation, neurodegeneration, and seizures (Criado et al., 2012; DePaoli-Roach et al., 2010; Ganesh et al., 2002; Tiberia et al., 2012; Valles-Ortega et al., 2011). *EPM2A* encodes laforin, the mammalian glycogen phosphatase, and *EPM2B* encodes malin, an E3 ubiquitin ligase (Gentry et al., 2007; Gentry, Worby, & Dixon, 2005; Worby, Gentry, & Dixon, 2006). The three-dimensional structure of laforin has been determined, elucidating the mechanism of its glycogen phosphatase activity (Raththagala et al., 2015). Both laforin and malin are believed to regulate the architecture of glycogen molecules and prevent the formation of LBs, although this mechanism has not yet been elucidated (Sullivan, Nitschke, Steup, Minassian, & Nitschke, 2017). Multiple groups have established that LBs drive neurodegeneration and epilepsy using these LD mouse models and complementary fly models (reviewed by (Gentry et al., 2018).

The polysaccharides from *Epm2a*^{-/-} and *Epm2b*^{-/-} mice that have been characterized were purified based on a method first described in 1909 by Pflüger for purifying glycogen, in which the tissue is boiled in KOH and the polysaccharides are precipitated with ethanol (Good, 1933; Pflüger, 1909). This method does not separate glycogen from the LBs.

122 Additionally, the Pflüger-purified polysaccharides differ in morphology from LBs observed
123 via microscopy in LD tissue sections. When analyzed by transmission electron microscopy
124 (TEM) the Pflüger-purified particles appear more aggregated than wild-type glycogen
125 (Tagliabracci et al., 2008), but they are dramatically smaller (15-65 nm) than the micron-
126 sized LBs observed in tissue sections (Minassian, 2001). Purification of LBs by the Pflüger
127 method likely disrupts LB morphology and also does not separate glycogen from the LB.
128 More recently, the “soluble” and “insoluble” fractions of glycogen were separated after tissue
129 homogenization and analyzed individually, revealing that only the “insoluble” fraction had an
130 altered chain length (Sullivan et al., 2019). The “insoluble” fraction is likely to correspond to
131 the LBs and the “soluble” fraction to normal glycogen, but this was not clearly demonstrated.
132 It is conceivable that LBs are aggregates of polyglucosan (i.e. abnormal polysaccharide)
133 molecules, and that the Pflüger method breaks apart the LBs and intermixes the polyglucosan
134 molecules comprising LBs with normal, soluble glycogen particles. In the case of starch,
135 many studies have shown that the application of heat and moisture results in solubilization
136 and irreversible disruption of the starch granular structure (Ratnayake & Jackson, 2009).

137 A significant body of work has been performed to define the chemical, physical and
138 structural properties of different types of starch, which vary depending on plant species and
139 tissue type (reviewed by (Lourdin et al., 2015). One of the major features that distinguishes
140 starch from glycogen is its semicrystalline, lamellar organization that can be detected with
141 diffraction techniques such as wide- and small-angle X-ray scattering (WAXS and SAXS,
142 respectively). Treatment of starch granules with mild hydrochloric acid, a process known as
143 lintnerization, preferentially hydrolyzes the amorphous regions, leaving crystalline regions
144 intact and providing valuable information about granule architecture (Gerard, Planchot,
145 Colonna, & Bertoft, 2000; Srichuwong, Isono, Mishima, & Hisamatsu, 2005; Wikman,

Blennow, & Bertoft, 2013). Despite the similarities between PGBs and starch, comparable methods have not yet been applied to investigate the structure of native PGBs.

In prior studies, variations of the Pflüger method were used to purify LD polyglucosan for biochemical analysis. NMR and enzymatic analyses demonstrated that LD polyglucosan contains elevated phosphate linked to the C2-, C3- and C6- hydroxyls of the glucose moieties in relatively equivalent ratios (DePaoli-Roach et al., 2015; Nitschke et al., 2013; Tagliabracci et al., 2011). Chain length distribution analysis showed an increase in longer chains in polyglucosan from muscle and brain, which causes the polyglucosan to precipitate (Irimia et al., 2015; Nitschke et al., 2017; Sullivan et al., 2019). These samples were always denatured; and native LBs were not analyzed. Furthermore, no biochemical study of isolated polyglucosan from cardiac tissue was performed. We recently described a novel method for isolating native LBs from *Epm2a*^{-/-} and *Epm2b*^{-/-} mice using a protocol that does not rely on the Pflüger method, separates LBs from glycogen, and preserves the endogenous size and structure of the LBs (Brewer et al., 2019). Using light microscopy and scanning electron microscopy, we showed that native LBs from brain, heart, and skeletal muscle have distinct sizes and morphologies, typically ranging from 2 to 10 µm in diameter, consistent with their distinct appearances in fixed tissue sections. We hypothesized that LBs possess starch-like biophysical and chemical properties, beyond just histochemical similarities, that distinguish them from normal glycogen. In the present study, we define the physiochemical and structural characteristics of native LBs isolated from different tissues. Combining these methods with thermal, mechanical and chemical treatments to disassemble LBs allows for a model of how polyglucosan molecules aggregate to form LBs in LD. Although not all PGBs are identical, the *corpora amylacea* of aging and neurodegeneration and the PGBs of multiple GSDs bear striking similarities to LBs. We propose that PGBs may represent a common

pathological phenomenon resulting from misregulated glycogen metabolism, which has particularly detrimental consequences in the brain.

2. Methods and Materials

2.1. Purification of native LBs from $Epm2a^{-/-}$ mice

All animal handling and procedures were approved by the University of Kentucky Institutional Animal Care and Use Committee (IACUC). $Epm2a^{-/-}$ mice have been previously described (DePaoli-Roach et al., 2012; Ganesh et al., 2002). Native LBs from 19-24 month old $Epm2a^{-/-}$ mice were purified as previously described (Brewer et al., 2019).

2.2. Confocal microscopy

20× Lugol's iodine was prepared as described previously (Brewer et al., 2019). For confocal microscopy, LBs or corn starch (Sigma) were stained with 20× Lugol's iodine, embedded in Mowiol 4-88 (Sigma cat #81381) on glass slides, and visualized using the TRITC channel (561 nm excitation laser) and differential interference contrast (DIC) using a Nikon AR+ Scope. Z-stack images of LBs were captured in 0.1 μ m steps, starch granules in 0.25 μ m steps, and 3D deconvolution was performed using the Nikon Elements Advanced Research Software. The Richardson-Lucy deconvolution algorithm was utilized with 10 iterations per stack.

2.3. Small- and wide-angle X-ray scattering (SAXS and WAXS)

Purified SmLBs and BrLBs were centrifuged at 14,000 rpm, and the wet pellets were poured into 1 mm (outer diameter) glass capillaries. For comparison purpose, capillaries containing potato amylopectin starch (PAPS) granules (a gift from E. Bertoft, Turku University) and rabbit liver glycogen (Fluka) were prepared as well. All specimens were

equilibrated for 5 days in a closed chamber maintaining a 93% relative humidity. The capillaries were flamed-sealed and X-rayed in air by a Ni-filtered CuK α radiation ($\lambda = 0.1542$ nm) using a Philips PW3830 generator operating at 30 kV and 20 mA. Two-dimensional scattering diagrams were recorded on Fujifilm imaging plates placed at a distance of about 5 cm from the capillary and read offline with a Fujifilm BAS 1800-II bioanalyzer. Diffraction profiles were calculated by rotationally averaging the 2D diffraction patterns after subtraction of the scattering signal from air. Capillaries containing SmLBs and BrLBs were also heated at 95 °C and analyzed immediately after heating and after 12 and 36 h at 4 °C. Considering the small amount of material, the specimens of acid-hydrolyzed LBs were centrifuged inside the capillaries and X-rayed in excess water. SAXS patterns were recorded from wet specimens (i.e. kept in excess water), with the imaging plates placed at a distance of 30 cm from the capillaries, and scattering profiles were calculated using the same rotational averaging procedure. SAXS data is usually presented as a function of the scattering vector, q (Blazek & Gilbert, 2011). WAXS profiles are presented as a function of the diffraction angle (2θ). The scattering vector (q) is geometrically related to the wavelength of the incident radiation (λ) and the scattering angle (2θ) (Figure S2). Therefore, q can be converted to distance of the repeating unit (d) in real space using Bragg's law:

$$q = \frac{4\pi}{\lambda} \sin \theta = \frac{2\pi}{d} \quad \text{Equation (1)}$$

2.4. LB treatments and light microscopy

SmLBs and BrLBs were aliquoted (100 μ g per tube) and washed in water by centrifugation at 16,000 g for 1 min. LB pellets were resuspended in 100 μ L water or 100 μ L 30% KOH for a final concentration of 1 mg/ml. For sonication treatment, five pulses of 5 seconds each were applied at 20 kHz with 25% amplitude, with one minute on ice between each pulse to prevent sample heating. For heat treatments at 95 °C, samples were heated for

30 min or 2 h as indicated. After treatment, 5 μ L of samples were stained with 2 μ L 20 \times Lugol's iodine, mounted on glass slides with a glass coverslip, and visualized using a Nikon Eclipse E600 using DIC/Nomarski contrast and an AxioCam MRm or Zeiss 512 camera at 100 \times . LBs had a tendency to flocculate, so after staining, samples were carefully triturated with a pipet, added to glass slides, and the coverslip was laid on top. The coverslip was very gently prodded and pressed to disperse the LB clumps and reduce the number of focal planes. Image thresholding was performed using the ImageJ software (National Institutes of Health, USA).

2.5. Hydrothermal and lintnerization treatments for transmission electron microscopy (TEM)

Two different treatments were performed to disrupt the LB structure and the resulting specimens were observed by TEM. In the first one, dilute aqueous LB suspensions were heated at 95 $^{\circ}$ C for 30 min, and TEM specimens were prepared after cooling down at room temperature and after keeping the suspensions for 3 days at 4 $^{\circ}$ C. The second treatment was carried out by disrupting LBs in 2.2 N HCl and incubating the suspensions at 36 $^{\circ}$ C. This gradual hydrolysis of glucose polymers in mild acid, a process known as lintnerization, is used to study crystalline structure (Bertoft, 2017; Jacobs, Eerlingen, Rouseu, Colonna, & Delcour, 1998). After 5 days, the suspensions were centrifuged; the pellets were repeatedly washed to neutrality by centrifugation in water and finally re-dispersed in water. Droplets of the various dilute suspensions were deposited onto glow-discharged carbon-coated copper grids. After blotting of the excess liquid, the preparations were negatively stained with 2 wt% uranyl acetate, allowed to dry and observed with a JEOL JEM 2100-Plus microscope operating at 200 kV and equipped with a Gatan Rio 16 camera.

2.6. Size Exclusion Chromatography (SEC)

Polyglucosan bodies were extracted/dissociated by boiling in 30% KOH for 1 h, followed by ethanol precipitation. This involved adding 4 volumes of ethanol with 15 mM LiCl and storing at -30 °C for 1 h. Samples were then centrifuged at 16,000 g for 20 min at 4 °C. Pellets were resuspended in 200 µL of milli-Q water and the ethanol precipitation step was repeated for a total of 3 times. Samples were freeze-dried overnight and then dissolved directly in SEC eluent (50 mM NH₄NO₃ with 0.02% sodium azide) at 80 °C and 350 rpm overnight. Samples were then analyzed using SEC as previously described (Sullivan et al., 2019). Briefly, dissolved polyglucosan (~2.5 mg.mL⁻¹) was injected into SHIMADZU LC-20AD system coupled with differential refractive index detector (Wyatt Technology, USA) using the following columns: SUPREMA preColumn, 1000 and 10,000 (PSS). The column oven was set at 80 °C, and the flow rate was set at 0.3 mL.min⁻¹. The differential refractive index detector was used to obtain the weight distributions, as previously reported (Sullivan et al., 2010). A universal calibration curve was constructed using pullulan standards (ranging from 108 to 1.22 × 10⁶ Da), also directly dissolved into the SEC eluent. Using the Mark-Houwink relationship the elution volumes were converted to hydrodynamic radius, as previously described in detail (Sullivan et al., 2010). Rat muscle glycogen was used as a reference for normal glycogen particles and was extracted using the same KOH method, as previously described (Sullivan et al., 2010).

3. Results

3.1. Confocal micrographs of iodine-stained LBs

Lugol's iodine is a chemical stain that has been used for over a century to detect and differentiate polysaccharides such as glycogen, amylose and amylopectin. Amylose, composed almost entirely of α-1,4 linear chains, produces a deep blue-black color when stained with Lugol's iodine, with a maximum absorption at 650 nm (Rundle, Foster, &

270 Baldwin, 1944; Swanson, 1948). The linear glucan chains of amylose form a complex with
271 iodine in the form of a single chromophoric helix. In contrast, the branch points within
272 amylopectin interfere with the interaction, producing a less stable complex with triiodide.
273 The result is a reddish-purple color and a maximum absorption at 550 nm (Swanson, 1948).
274 Glycogen contains even shorter chains and more frequent branching than amylopectin, and
275 therefore stains poorly with Lugol's iodine. Glycogen yields an absorbance maximum at 440
276 nm, although this varies slightly depending on glycogen source, i.e. glycogen from different
277 tissues and/or organisms (Archibald et al., 1961).

278 Iodine staining of LBs, *corpora amylacea*, and other PGBs indicates a branching degree
279 that is more similar to amylopectin than glycogen (Herrick, Twiss, Vladutiu, Glasscock, &
280 Horoupian, 1994; Reed Jr, Dixon, Neustein, Donnell, & Landing, 1968; Sakai et al., 1969).
281 We previously showed that native LBs isolated from skeletal muscle, heart tissue, and brain
282 of *Epm2a*^{-/-} mice stained intensely reddish-brown in Lugol's iodine with an absorbance
283 maximum at approximately 510-520 nm (Brewer et al., 2019). The iodine-stained LBs not
284 only absorb at this wavelength, but they also produce red fluorescence when excited by a 561
285 nm confocal laser. Confocal microscopy has previously been used as a sensitive method for
286 visualizing starch granules *in vitro* and *in planta* (Bahaji et al., 2011; Ovecka et al., 2012). Z-
287 stack images of iodine-stained starch granules visualized using the 561 nm laser and
288 differential interference contrast (DIC) at high magnification show that only the smooth,
289 outer edge of the granule is stained (Figure 1A and B, Figure S1A through D). This staining
290 pattern indicates that iodine more efficiently penetrates the outer portion than the densely
291 packed semicrystalline interior of the starch granule.




Figure 1. Representative z-stack confocal images via the 561 nm laser line of iodine-stained starch (A), SmLBs (C), HtLBs (E), and BrLBs (G,I). Differential interference contrast (DIC) is also shown for each: starch (B), SmLBs (D), HtLBs (F), and BrLBs (H,J). In (A) and (B), scale bar = 10 μ m and TRITC panels represent 2 μ m steps. In (C) through (I), scale bar = 2 μ m. For SmLBs (C), TRITC panels represent 0.4 μ m steps. For HtLBs (E) and BrLBs (G, I) TRITC panels represent 0.9 μ m steps.

Isolated LBs from *Epm2a*^{-/-} skeletal muscle (SmLBs) have a characteristic ovoid morphology and are typically 1-3 µm in length (Brewer et al., 2019). Like starch, they also fluoresce brightly with 561 nm excitation after iodine staining, but they display staining throughout the LB, suggesting their smaller size and less dense interior facilitates greater penetration of the triiodide ions (Figure 1C and 1D, Figure S1E through H). LBs isolated from *Epm2a*^{-/-} hearts (HtLBs) are larger in size (typically 2-4 µm, up to 10 µm in length) and more elongated than SmLBs (Brewer et al., 2019). They were also stained homogeneously with iodine and were comprised of a visible interior texture and a brighter rim (Figure 1E, Figure S1I and S1K). The textured surface of the LBs was evident using DIC and consistent with what we previously observed via scanning electron microscopy (Figure 1F and 1H) (Brewer et al., 2019). Brain LBs (BrLBs) were also larger in size (typically 2-4 µm, occasionally >10 µm in diameter) and varied in morphology more than SmLBs and HtLBs. Some BrLBs were very round and homogeneously stained, with a bright rim and textured appearance, similar to HtLBs except that they are not typically elongated (Figure 1G and 1H). Some BrLBs had a very jagged edge with a dense core that did not stain well with Lugol's iodine (Figure 1I and 1J). Very small iodine-positive granules were also evident around LBs from heart and brain (Figure 1 and Figure S1), consistent with previous observations describing "dust-like particles" (Brewer et al., 2019; Van Hoof & Hageman-Bal, 1967). Overall, the fluorescence produced from the interaction of LBs with the triiodide ions suggests they possess crystalline regions like plant starch. In general, the LBs are more permeable to the triiodide ions than starch, indicating less compact and/or less orderly architecture. However, the lack of central iodine fluorescence in some of the BrLBs (Figure 1I) suggests that some bodies had a more densely packed center, like that of starch (Figure 1A, Figure S1A and S1C).

3.2. *LBs contain B-type crystallites lacking long-range order*

Unlike glycogen, starch granules possess both short- and long-range order, which can be measured by X-ray scattering techniques. Long-range order refers to the alternation of crystalline and amorphous layers within the growth rings of the starch granule (i.e. lamellae), with a repeat distance of 8-10 nm (Figure 2A, panels *I* and *II*) (Blazek & Gilbert, 2011; Lourdin et al., 2015). Small-angle X-ray scattering (SAXS) is better suited for measuring these nanometer-sized distances (Figure S2A) (Donald, Kato, Perry, & Waigh, 2001). Short-range order refers to repeating units on the sub-nanometer scale, i.e. the crystalline organization of double helices formed by the short linear segments of amylopectin (Figure 2A, panels *III* and *IV*). Wide-angle X-ray scattering (WAXS) is used to probe sub-nanometer-sized distances and has been widely utilized to study crystallinity in starch and other polymers (Figure S2A) (Blazek & Gilbert, 2011; Donald et al., 2001). In starch, amylopectin double helices crystallize in two different allomorphs depending on the starch source (e.g. potato or corn). Typically, A-type is found in cereals while B-type occurs in tubers and high-amylose starch (Bertoft, 2017; Qiao et al., 2017). The allomorphic composition can be determined from X-ray diffraction patterns. The double helices of A-type crystals are densely packed into a monoclinic unit cell that contains little water (Figure 2A, panel *V*) (Popov et al., 2009). In the B-type crystal, the double helices form a hexagonal network with a central channel that contains water molecules, rendering this allomorph more open and hydrated (Figure 2A, panel *VI*) (Imberty & Perez, 1988). We used SAXS and WAXS to characterize the order in native, purified LBs.




Figure 2. (A) Schematic depiction of long- and short-range order within the starch granule. *I*: An ultrathin section of a waxy maize starch granule visualized by transmission electron microscopy (TEM) and showing the typical growth rings. *II*: Growth rings are composed of alternating amorphous and semicrystalline layers (known as lamellae). *III*: Semicrystalline lamellae are made up of branched amylopectin molecules with amorphous regions containing the branch points and a crystalline region containing the linear segments forming double helices. The total lamellar thickness equals the so-called repeat distance which is typically 8–10 nm (Nakamura, 2015). The arrangement of the crystalline clusters is still debated. *IV*: Long, linear glucan chains (black lines) form double helices that make up the crystalline layers of the starch lamellae. The helical packing determines the allomorphic type. *V*: In A-type, the helices (grey circles) are closely packed, with some water molecules (blue circles) in-between. *VI*: In B-type, the helices form a hexagonal array surrounding a water-filled channel (Imberty & Perez, 1988; Nakamura, 2015; Tester, Karkalas, & Qi, 2004). Reprinted by permission from Springer Nature: Springer, Crystalline Structure in Starch, Lourdin et al. © 2015. (B) SAXS profiles of LBs and potato amylopectin starch (PAPS). (C) WAXS profiles of BrLBs and SmLBs compared to those of PAPS and rabbit liver glycogen. (D) WAXS profiles of SmLBs after heating at 95 °C and cooling down to room temperature, and then with a retrogradation period at 4 °C either 12 or 36 h after heating at 95 °C. Grey lines denote the location of characteristic B-type reflections in WAXS profiles. The corresponding 2D SAXS and WAXS patterns are shown in Figure S3.

We first performed SAXS on SmLBs. As a control, we also analyzed a genetically modified starch engineered to contain exclusively amylopectin and no amylose called potato amylopectin starch (PAPS) (Svegmark et al., 2002). PAPS produced a characteristic SAXS profile with two distinct peaks (Figure 2B and Figure S3A). The peak at $q = 4.1 \text{ nm}^{-1}$ corresponds to a d -spacing of 1.53 nm and is equivalent to the innermost reflection of the B-

type allomorph in a WAXS profile. It corresponds to the spacing of (100) planes in the unit cell (Figure S2A). The reflection at $q = 0.76 \text{ nm}^{-1}$ corresponds to a repeat distance of 8.3 nm (Figure 2B), i.e. the lamellar repeat in the amylopectin structure (Figure 2A, panel III) (Blazek and Gilbert 2011). While the profile of SmLBs also contained the (100) reflection of B-type, the peak corresponding to the lamellar repeat was absent (Figure 2B and Figure S3B). This result indicates that SmLBs do not contain any lamellar units like starch granules.

To establish whether LBs are crystalline, we studied them using WAXS with PAPS as a control. We analyzed both SmLBs and BrLBs to determine whether there are allomorphic differences between LB types. PAPS, SmLBs and BrLBs all produced a WAXS diffraction pattern containing characteristic reflections of the B-type allomorph at $2\theta = 5.6, 17, 22$ and 24° (Figure 2C, S3C, S3D and S3E) (Buléon, Bizot, Delage, & Pontoire, 1987). The WAXS reflection at $2\theta = 5.6^\circ$ corresponds to the 100 reflection, a typical signature of allomorph B (Svegmark et al., 2002). Using Equation (1), d -spacings were calculated from these values of 2θ and are in agreement with those of B-type potato starch (Table 1, also see Figure S2B) (Cleven, Van den Berg, & Van Der Plas, 1978). In contrast, rabbit liver glycogen can be considered amorphous since its WAXS profile does not contain any distinct peak (Figure 2C).

Table 1. d -Spacings (in nm) calculated from the position (diffraction angle 2θ) of the diffraction peaks in the WAXS profiles of PAPS and LB samples using Equation (1) compared to published values (*from Cleven et al. 1978).

Peak #	1	2	3	4
PAPS	1.59	0.52	0.40	0.37
SmLBs	1.59	0.52	0.40	0.37
BrLBs	1.59	0.52	0.40	0.37
Potato*	1.58	0.53	0.40	0.37

When starch is heated in water, it swells and amylose leaches out of the granule. The peak in the SAXS profile disappears, indicating that the lamellae organization is disrupted and no longer present. The peaks in the WAXS profile concomitantly disappear due to the complete loss of crystal structure, i.e. glucan chains are no longer oriented in repeating helical units (Cameron & Donald, 1992). However, after gelatinization, as the starch cools down to room temperature, amylose and amylopectin regain B-type crystallinity, a process known as retrogradation. Double helices form from intra- and intermolecular interactions, and aggregate into networks (Putaux, Buleon, & Chanzy, 2000). However, in retrograded starch, the lamellar periodicity of the native granule does not return (Cameron & Donald, 1991). To test the effect of heat denaturation of LBs, we heated SmLBs at 95 °C, analyzed them by WAXS, and observed that the B-type reflections were significantly reduced (Figure 2D). However, when the samples were incubated for 12 or 36 h at 4 °C post-heating, the reflections gradually reappeared (Figure 2D). These data indicate that solubilized LBs structurally behave like retrograding starch: crystallinity is reduced upon heating but reappears spontaneously in a B-type arrangement after incubation at low temperature.

3.3. Microscopic effects of mechanical, thermal and chemical treatments on LBs

Thus far, the data demonstrate that LBs are comprised of B-type crystallized glucan chains. As discussed in the introduction, the Pflüger method involves both thermal and chemical treatment resulting in the conversion of micron-sized LBs to nanometer-sized particles. Since modification of starch and other polysaccharides by mechanical, thermal, chemical, or enzymatic means provides structural insights, we sought to explore the effects of multiple treatments on LB structure by light microscopy and iodine staining.

Untreated SmLBs are uniformly small and ovoid and stain intensely with Lugol's iodine (Figure 3A). We found that mild sonication (5 x 5 s at 20 kHz with 25% amplitude) disrupted

SmLB structure almost entirely (Figure 3B). After this treatment, most of the LBs were fragmented into clumped, lace-like networks of polyglucosan material that lightly stained with Lugol's. Only a few intact SmLBs were left associated with the lace-like networks (Figure 3B, inset). This result is quite different from what has been observed with starch granules: treatment of starch granules with ultrasonication for minutes or longer produces only mild disruption of granular structure (Majzoobi, Seifzadeh, Farahnaky, & Mesbahi, 2015).

We next examined the effect of heat denaturation on LB structure. SmLBs were heated in water for 30 min at 95 °C and were completely converted to lacy networks (Figure 3C). The resulting material after heating appeared very similar to the material produced by sonication, except that no intact SmLBs were observed after the heat treatment. The clumps of material were even more dispersed with longer heating (2 h at 95 °C), and very small, freely floating particles with diameters less than 1 µm were more abundant (Figure 3D).

Since the Pflüger method is the standard technique used to precipitate glycogen and has been often employed to purify polysaccharides from LD mice (Sullivan et al., 2019; Tagliabracci et al., 2008), we next analyzed the effects of this treatment on SmLB structure. In this method, the tissue is boiled in 30% KOH for 2 h, the polysaccharide is precipitated three times with 2 volumes of cold ethanol, and then it is re-dissolved in water. LiCl is added with the ethanol to ensure complete precipitation (Tagliabracci et al., 2008). The successive precipitation steps remove impurities and residual KOH, and the resulting individual particles can be analyzed by TEM or SEM (Sullivan et al., 2019; Tagliabracci et al., 2008). To test the contribution of the different portions of the Pflüger method on LB structure, we performed 2 h heat treatments in either water (i.e. hydrothermal) or 30% KOH, followed by ethanol precipitation. The SmLBs that were precipitated with ethanol and LiCl three times following




Figure 3. Effects of multiple treatments on the structure of LBs. LBs were stained with Lugol's iodine after each treatment and visualized by light microscopy. Control SmLBs (A); mildly sonicated SmLBs (B); SmLBs heated in water at 95 °C for 30 min (C); SmLBs heated

in water at 95 °C for 2 h (D); SmLBs heated in water at 95 °C for 2 h, then precipitated 3 times with 2 volumes cold ethanol and LiCl (E); SmLBs treated with the Pflüger method (2 h at 95 °C in 30% KOH) (F). Control BrLBs (G); BrLBs heated in water for 30 min (H); BrLBs treated with the Pflüger method (I). Thresholding was used to quantitate LBs (with high intensity staining) and polyglucosan (with low intensity staining) in micrographs. Examples of applied thresholds for (G) through (I) are shown in (J) through (L). Pixels with high intensity (grey values 0-50) and low intensity (grey values 51-140) were counted and shown as a percentage of total counted per micrograph. Pixels with grey values above 141 were considered background and not counted. The values shown are the averages of 9 micrographs \pm standard error. (N, O, P) Structural transition of SmLBs during heating. Control SmLBs (N), SmLBs heated for 1 minute and flash frozen (O), and SmLBs heated for 5 min and flash frozen (P). After freezing, samples were thawed, stained with Lugol's iodine, and visualized using a light microscope with a Zeiss 512 color camera. All scale bars = 10 μ m. Each inset is a 2.5x magnification of the boxed region.

a 2-h boil in water were more difficult to resuspend in water: the white pellet did not easily go into solution, and flakes of polysaccharide were visible. Using light microscopy, this material contained intensely stained aggregates, filamentous structures and granular particles (Figure 3E). The aggregates were more amorphous and less compact than control SmLBs, but stained with a similar intensity, suggesting that the polyglucosan became re-crystallized with precipitation. However, the LBs that underwent precipitation after a 2-h hydrothermal treatment did not reform into the compact, ellipsoidal shape of native SmLBs (Figure 3F). In contrast, LBs that were boiled in 30% KOH for 2 h and then precipitated three times with ethanol and LiCl were very easily re-suspended in water and produced no visible precipitate. This material did not contain intensely-staining aggregates with Lugol's solution and only a few small clumps of polyglucosan material were visible (Figure 3F). Thus, boiling in KOH instead of water fully dissociates the LBs into polyglucosan particles rather than networks, and in these alkaline conditions, the polyglucosan is much less prone to re-aggregate upon ethanol/LiCl precipitation.

Hydrothermal and Pflüger treatments were also applied to BrLBs and the products were visualized via light microscopy. As expected, in the absence of treatment BrLBs were larger

and more irregularly shaped than SmLBs and stained with Lugol's iodine (Figure 3G). A 30-min hydrothermal treatment partially converted BrLBs to polyglucosan networks, though some BrLBs remained intact, surrounded by the lacy material (Figure 3H). As with the SmLBs, Pflüger treatment released a large amount of small granular particles, but more lacy polyglucosan was still present in these samples compared to the Pflüger-treated SmLBs (Figure 3I versus 3F). These samples were also easy to re-suspend after precipitation.

Image thresholding was used to quantitate LBs, LB-like aggregates and the lace-like polyglucosan in treated samples. In the recorded micrographs, intact LBs were very dark grey or black, with grey values of 50 or less (Figure 3J and K). Polyglucosan networks or particles appeared in lighter shades of grey, with values between 51 and 140 (Figure 3K and L). Pixel counts from multiple micrographs showed that >95% high intensity staining (i.e. intact LBs) were disrupted by sonication and heating in water for 30 min (Figure 3M). No intact LBs were found in the SmLB samples that were heated in water for 2 h or the Pflüger-treated samples. Interestingly, the high intensity observed in control samples (53% of counted pixels) could be partially restored by ethanol treatment after heating for 2-h in water (25% of counted pixels). These results demonstrate that crystalline LBs undergo a structural transition to polyglucosan networks in the presence of heat, and they can be fully dissociated with the Pflüger method. Without KOH, ethanol precipitation causes polyglucosan to re-aggregate and form dense, LB-like structures.

To visualize the transition from native LB to lacy polyglucosan networks, SmLBs were heated at 95 °C for 1 or 5 min in water, immediately flash frozen in liquid nitrogen, thawed, and stained with Lugol's iodine. Control, native LBs stained bright reddish-brown in Lugol's iodine (Figure 3N). Samples that were heated for 1 min displayed numerous amorphous, reddish-brown gelatinous structures in addition to small fragments of lightly stained lace-like polyglucosan (Figure 3O). By 5 min, only lace-like polyglucosans were visible, and no

gelatinous structures were observed (Figure 3P). These results are strongly reminiscent of gelatinization, the irreversible order-disorder transition that starch undergoes when heated in water characterized by swelling, increased viscosity and a loss of crystallinity (Ratnayake & Jackson, 2006). These results strongly suggest that like starch, LBs gelatinize at high temperatures.

3.4. TEM observation of hydrothermally-treated and lintnerized LBs

Normal glycogen particles can easily be visualized using transmission electron microscopy (TEM) (Revel, Napolitano, & Fawcett, 1960; Ryu et al., 2009). To study the structure of disrupted LBs with higher resolution than can be achieved by the light microscope, the hydrothermally-treated SmLBs were analyzed by TEM. After heating samples for 30 min at 95 °C, they were allowed to cool to room temperature, stained with uranyl acetate, and visualized. Two types of species were observed: i) individual spheroidal particles with diameters ranging from 15 to 25 nm and appearing similar to typical glycogen granules (Ryu et al., 2009) and ii) knobby worm-like objects (Figure 4A). The worm-like objects had widths varying between 5 and 15 nm, bearing a strong resemblance to retrograded amylopectin (Putaux et al., 2000). BrLBs were also visualized by TEM after a 30-min hydrothermal treatment (Figure 4B). The individual sponge-like particles were slightly smaller in size (12 to 23 nm), irregular, and difficult to distinguish; the worm-like objects were also present, with a similar width to those of the SmLBs. After heating, the SmLB and BrLB samples were also incubated at 4 °C to determine whether the particles would aggregate into networks, i.e. retrograde, in a manner similar to amylopectin. Indeed, after 72 h, larger networks formed that appeared to be aggregates of the worm-like elements observed after the initial solubilization at 95 °C (Figure 4C and 4D). However, individual glycogen-like particles that did not aggregate in the SmLBs samples were still observed




Figure 4. Transmission electron microscopy (TEM) observation of LB structure. (A, B, C, D) TEM images of negatively stained specimens prepared by heating dilute aqueous SmLB (A, C) and BrLBs (B, D) suspensions at 95 °C for 30 min. The specimens were observed immediately after cooling them to room temperature (A, B) and after 3 days (72 h) at 4 °C (C, D). (E, F) Images of negatively stained specimens prepared by hydrolyzing LBs in 2.2 N HCl for 5 days at 36 °C: (E) SmLBs; (F) BrLBs. Scale bars = 100 nm.

(Figure S4). Interestingly, retrograded amylopectin takes on a very similar necklace-like appearance where over time the molecules associate to form networks (Putaux et al., 2000). These data are consistent with the re-formation of B-type crystallinity after a cooling period post-heating (Figure 2D). Like amylopectin, polyglucosan particles of LBs can retrograde, i.e. spontaneously form crystalline associations via intermolecular helical interactions to form a network or necklace-like pattern.

Lintnerization is the process of treating starch granules with mild HCl at sub-gelatinization temperatures for long periods of time (Bertoft, 2017; Jacobs et al., 1998). The amorphous regions of the starch granule hydrolyze early during lintnerization, while crystalline regions are left intact. This effect is due to the protection of glucose residues and glycosidic linkages within the crystalline lamellae containing the double helices, which are less easily penetrated by the hydrogen ions (Jacobs et al., 1998; Putaux, Molina-Boisseau, Momaur, & Dufresne, 2003). The morphology and properties of the lintners, the insoluble residues after hydrolysis, vary with species, amylose content, and starch allomorph (Goldstein et al., 2016; Putaux et al., 2003; Wikman et al., 2014). This process allows the crystalline residues of the starch to be analyzed in isolation.

BrLBs and SmLBs were treated with 2.2 N HCl for 5 days at 36°C, washed with water and imaged by TEM after negative staining. The BrLB and SmLB lintners were very similar in morphology, both appearing as lacy networks of flat elements (Figure 4E and 4F). Similar lacy networks have been reported for lintnerized potato starch, particularly waxy potato starch, which exhibit B-type crystallinity (Wikman et al., 2014). This result is in contrast to A-type waxy maize starch or barley starch lintners that form well-defined polyhedral platelet nanocrystals, reflective of A-type helix packing (Goldstein et al., 2016; Putaux et al., 2003).

3.5 Size distribution of the polyglucosan particles in LBs

When visualized by TEM, normal glycogen particles typically appear as individual granules ranging from 20 to 50 nm in diameter, but can form large α rosettes in the liver (Ryu et al., 2009). Heated SmLBs contained individual particles from 15 to 25 nm in diameter, which appeared similar to normal glycogen (Figure 4A and 4C). However, heated SmLBs and BrLBs both contained worm-like elements with a diameter of 5-15 nm after heating and unambiguous B-type lintners after treatment with mild acid. Such structures are quite distinct from the normal structure of glycogen and may result from an aggregation of very small or very long polysaccharide particles.

To determine the distribution of particle sizes within the LB preparations, native SmLBs, BrLBs and HtLBs were dissociated into polyglucosan particles via the Pflüger method and then analyzed using size exclusion chromatography (SEC). Rat muscle glycogen was used as a reference for normal glycogen particle distribution, with a single peak corresponding to particles with hydrodynamic radius (R_h) ~10-20 nm (Figure 5). All LB samples displayed a very narrow peak at R_h ~1 nm, likely too small to be a polyglucan (estimated to be the approximately the same size as an oligosaccharide or peptide). Beyond this peak, SEC data for SmLB particles were consistent with size distributions of polysaccharide from *Epm2a*^{-/-} skeletal muscle as previously published (Sullivan et al., 2019): a primarily bimodal distribution with the first major peak at hydrodynamic radius (R_h) ~3 nm and the second at R_h ~10-15 nm. The second peak is consistent with the size of rat muscle glycogen particles and previous reports of glycogen from various sources (Sullivan et al., 2019; Sullivan et al., 2014). The polyglucosan particles from BrLBs and HtLBs, however, lacked the peak at R_h ~10-15 nm, and contained only a major peak at R_h ~3 nm (Figure 5). These striking results indicate that pure SmLBs contain a variety of particle sizes, with an enrichment of particles comparable in size to glycogen and very small particles. In contrast, dissociated BrLBs and HtLBs contain exclusively very small particles, which are likely to form early during

glycogen synthesis (Sullivan et al., 2019). The worm-like aggregates and networks that were observed after heating via TEM (Figure 4A, B, C and D) are likely to be aggregates of the small particles with $R_h \sim 3$ nm (i.e. roughly 6 nm in diameter), since retrogradation and re-aggregation can rapidly start upon cooling the suspension (Michen et al., 2015). The absence of the individual glycogen-like particles in the BrLB samples in Figure 4 is consistent with the SEC data.





Figure 5. SEC weight distributions, $w(\log R_h)$ of KOH-dissociated polyglucosan particles from BrLBs (green), HtLBs (red) and SmLBs (blue), as a function of hydrodynamic radius, R_h . Rat muscle glycogen was used as a reference (black). Normalization is arbitrary with SEC weight distributions and was chosen to be at the peak with an R_h of ~ 1 nm.

4. Discussion

4.1. Proposed model for LB architecture and formation

We describe three levels of polyglucosan architecture in our study: the native LB, the polyglucosan network, and the polyglucosan particle. The largest entity is the native LB, typically ranging in diameter from 2-10 μm (Figure 6). In heart and brain, LBs consist only of very small polyglucosan particles, while in skeletal muscle, LBs contain a mixture of glycogen-like particles and very small polyglucosan particles. Minimal branching favors B-type crystal packing, where double helices form a hexagonal unit with a water-filled interior channel. It is possible that some double helices are formed from adjacent chains within the same polyglucosan molecule (intramolecular interactions), while others may be formed from



617

Figure 6. A model for LB structure and formation, as in heart and brain. Blue arrows and text illustrate what was observed *in vitro*, and red arrows and text illustrate an *in vivo* model. LBs are primarily comprised of very small polyglucosan particles with abnormally long glucan chains that can crystallize into the B-type allomorph. LBs (i.e. intact PGBs) can be disrupted into networks by sonication, heat, or acid, and the individual particles can be completely dissociated via the Pflüger method. Aggregation of these polyglucosan particles into networks is likely to occur spontaneously *in vivo* since we observed spontaneous retrogradation *in vitro* after 72 hours at 4 °C. Since LBs have a very defined structure, active cellular sequestration is likely responsible for the distinct tissue-specific morphologies. LBs in skeletal muscle also contain glycogen-like particles (not shown).

628

629

chains from two different polyglucosans (intermolecular interactions). For most LB types,

crystalline units are randomly arranged, in stark contrast to the lamellar structure of starch

granules. The only exception is BrLBs where in some granules iodine did not penetrate to the

center. These results are consistent with previous TEM studies suggesting some LBs are

composed of radially arranged fibrils and a dense core (Berard-Badier et al., 1980; Cavanagh,

1999; Ishihara et al., 1987).

The second structural entity is the polyglucosan network that emerges when intact LBs are heated, mechanically agitated, or lintnerized (Figure 6). These networks resemble potato lintners and retrograded (i.e. re-precipitated) amylopectin, both of which exhibit B-type crystallinity (Putaux et al., 2000; Wikman et al., 2014). Since amylopectin and LD polysaccharide are both infrequently branched polysaccharides with long glucan chains capable of crystallizing, it is not surprising that the two polysaccharides would associate in a similar network formation. The networks are composed of knobby fibers between 5 and 20 nm in diameter. The morphology has been described as resembling a necklace, where the "pearls" are laterally packed helical bundles connected by longer amylopectin chains (Putaux et al., 2000). In the case of LD, it is likely that molecules associate via intermolecular helical interactions to form these necklace-like fibers (Figure 6).

The third structural entity is the polyglucosan particle (Figure 6). This particle is presumably an aberrantly branched glycogen β -particle with such long chains that it crystallizes. We have shown that polyglucosan particles are best dissociated with Pflüger treatment, due to heating in KOH. Indeed, alkaline treatment increases the solubility of both glycogen and starch (Kerly, 1930; Wang et al., 2014), and certain forms of these polysaccharides (desmoglycogen or 'fixed' glycogen and resistant starch) can only be solubilized with alkali (Perera, Meda, & Tyler, 2010; Stetten, Katzen, & Stetten, 1958). This phenomenon is likely simply because alkali solutions disrupt hydrogen bonding between hydroxyl groups of neighboring glucosyl units (Thys et al., 2008). Once dissociated, SEC distributions show an enrichment of molecules smaller than typical glycogen particles, most prominently in the brain and heart (Figure 5). Dissociated polyglucosan particles from skeletal muscle are comprised of small molecules of $R_h \sim 3$ nm (i.e. ~ 6 nm in diameter) and also contain molecules similar in size to regular muscle glycogen with a peak R_h of ~ 10 - 15 nm (i.e. ~ 20 - 30 nm in diameter). These data are in agreement with previous reports while

providing additional insights (Sullivan et al., 2019). These results indicate that glycogen from LD mice may be particularly vulnerable to precipitate early during synthesis of the glycogen granule, before it reaches its normal size (~25 nm). Dissociated polyglucosan bodies from the skeletal muscle, heart and brain all also contain a peak at an R_h of ~1 nm (estimated to be the size of a short oligosaccharide or peptide). Whether this is small carbohydrate or protein that is associated with LBs is unknown and is being further explored.

In starch, the crystalline, double helical conformation of glucan chains retards their access by degrading enzymes (Emanuelle et al., 2016). Presumably, the long chains of polyglucosan particles take on a similar conformation and prevent them from being degraded by the glycogenolytic machinery (Sullivan et al., 2017). As a result, polyglucosan particles accumulate, potentially associating into networks inside of cells like the ones we observed *in vitro* (Figure 6). Since we observed that LBs undergo retrogradation (Figure 2D, 5C and 5D), crystallization and network formation likely occur spontaneously, similar to the natural retrogradation of amylopectin after it is cooked. It is likely that the cell, detecting an unknown and potentially toxic species, sequesters the spontaneously forming polyglucosan networks into non-membrane-bound inclusions that become LBs. LBs have been shown to be decorated with a variety of proteins involved in glycogen metabolism, ER stress, ubiquitin, and autophagy and delineated by cytoskeletal elements *in vivo* (Criado et al., 2012; Machado-Salas et al., 2012). Thus, the formation of this structural entity may not be entirely spontaneous; cellular mechanisms may assist in polyglucosan sequestration. We showed that ethanol precipitation of LBs after boiling in water led to some polyglucosan clumps that stained as intensely as native LBs. This treatment may in some way resemble the process of active polyglucosan sequestration that occurs in cells. The shape and size of the LB is likely dictated by the internal constraints of the cell type where it forms, but it may also be

influenced by the CLD of the constituent polyglucosan and/or effects of surrounding molecules.

The lack of higher order in LBs is not surprising, given that they are an aggregate that forms in response to an aberrant cellular mechanism. B-type crystallization is favored by longer chains and lower temperatures (Cai & Shi, 2013; Gidley & Bulpin, 1987). Even native A-type amylopectin can take on a B-type conformation after retrogradation (Qiao et al., 2017). A previous study showed that the *in vitro* enzymatic chain elongation of glycogen produced dendritic particles with B-type crystallinity (Putaux, Potocki-Véronese, Remaud-Simeon, & Buleon, 2006). TEM micrographs suggest that over time, double helical segments formed as a result of intra- and intermolecular entanglement of the extended glucan chains. It has been proposed that in LD, the lack of laforin or malin leads to an imbalance in glycogen synthase and branching enzyme activities, causing aberrant chain elongation (Sullivan et al., 2017). Thus, the entanglement and crystallization of artificially elongated glycogen as described by Putaux et al. (2006) may resemble what occurs *in vivo* in LD.

4.2. Nomenclature: polysaccharides, glycogen, polyglucosan, PGBs and LBs

Terminology choices have been carefully considered in this study. The term 'polysaccharide' denotes any polymer of sugar molecules, and thus glycogen, amylopectin, amylose, and polyglucosan are all polysaccharides. The term 'polyglucan' refers only to polysaccharides containing glucose units attached by glycosidic bonds, and more specifically, α -polyglucans are those with α -1,4 and α -1,6 glycosidic bonds. Thus, all of the polysaccharides discussed in this paper are also α -polyglucans. However, we abstained from using the term 'polyglucan' due to its similarity to 'polyglucosan' and also since no other types of polysaccharides are discussed.

The polysaccharides purified from LD mice via the Pflüger method are frequently called 'glycogen', and LD mice are said to have increased glycogen in their tissues. However, studies of the polysaccharide content of 'insoluble' vs. 'soluble' glycogen fractions in LD mice show that LD mice display an increase in the insoluble fraction, but the soluble fraction (i.e. normal glycogen) is equivalent to wild-type (WT) mice (DePaoli-Roach et al., 2010; Sullivan et al., 2019). The Pflüger purified polysaccharides are actually a mixture of both normal glycogen and abnormal polysaccharides that we refer to herein as polyglucosan. LD tissues have approximately the same amount of soluble glycogen as WT mice, and the total increase in polysaccharide, is exclusively due to insoluble polyglucosan (Sullivan et al., 2019; Sullivan et al., 2017). The polyglucosan of LD is a precipitation-prone polysaccharide with long chains and a molecular size much smaller than the typical glycogen particle that can form B-type crystalline units. This material is quite divergent from the typical definition of glycogen, i.e. a soluble glucose polymer with ~13 glucose units per chain, regular branching, and an average diameter of about 25 nm (i.e. 10,000 glucose units) (Brewer & Gentry, 2019; Roach, 2002). Therefore, the abnormal polysaccharide should be called polyglucosan rather than glycogen.

One should also recognize the difference between 'polyglucosan', 'polyglucosan bodies' (PGBs), and 'LBs'. Polyglucosan refers to any abnormal glucose polymer containing α -glycosidic linkages found in mammalian tissues, but its exact chemical characteristics vary with its pathological origin. 'PGBs' refer to the compacted inclusions of polyglucosan observed *in vivo*, which can be isolated as intact entities (Brewer et al., 2019; Sakai et al., 1969; Yokoi et al., 1968). *Corpora amylacea* and LBs are considered PGBs, but not all PGBs are exactly equivalent. 'LBs' are the PGBs found in LD, which we have shown are morphologically distinct based on tissue type. Additionally, in this study, we specifically used the term 'disrupt' to refer to any modification of the PGB structure, such as by

sonication or heating, while ‘dissociate’ referred to the complete separation of individual polyglucosan particles via the Pflüger method.

4.3. Similarities of LBs with other PGBs and amyloid and their relevance to neurological disease

PGBs of different pathologies are overall very similar but distinguishable by subtle ultrastructural and histochemical qualities. LBs are the only PGB to display a darkly staining central core with radiating fibrils visible by electron microscopy (Cavanagh, 1999). The polyglucosan fibrils in LBs are somewhat thicker and more electron dense than those in the PGBs of GSD IV, a disease caused by a deficiency in glycogen branching enzyme (GBE) (Ishihara et al., 1987). With Lugol's iodine, LBs are brown, *corpora amylacea* are purplish-brown, and the GSD IV PGBs are distinctly purple, reflecting their abnormally long glucan chains (Reed Jr et al., 1968; Sakai et al., 1969; Sullivan et al., 2019). The PGBs of GSD IV do not stain with toluidine blue, in contrast to *corpora amylacea* and LBs, suggesting they have a much lower phosphate content (Reed Jr et al., 1968). Furthermore, a recent study reported that polyglucosan from GBE mutant mice (a model of Adult Polyglucosan Body Disease) had normal levels of phosphorylation at the 6-hydroxyls and even longer chains than LD polyglucosan (Sullivan et al., 2019). According to another study, *corpora amylacea* had even more phosphate than LBs (Sakai, Austin, Witmer, & Trueb, 1970). The data presented in the present study on LBs are likely to be very relevant to understanding the architecture and formation of other PGB types. It is likely that the aggregation of polyglucosan into networks and B-type crystallization are common features of PGBs. It will be very interesting to compare their CLD profiles and particle size distribution and chemical compositions to understand their architectures and *in vitro* properties.

758 The different levels of polyglucosan association (PGB, network, and particle) are
759 analogous to the levels of protein aggregation in amyloid disorders. Polyglucosan particles
760 aggregate into networks much like misfolded proteins aggregate into soluble amyloid
761 oligomers. Eventually the polyglucosan compacts into PGBs, and soluble oligomers
762 polymerize into fibrils and plaques, although these higher-orders structures are distinctly
763 different. For example, PGBs contain crystalline α -helices, while amyloid contains β -sheets;
764 polyglucosan fibrils are branched, but amyloid fibrils are not; PGBs are typically not
765 birefringent, in contrast to amyloid. It is possible that for both types of inclusion, the
766 intermediate aggregates are toxic, and the higher-order structures are reactionary, or even
767 protective. There is a significant amount of evidence supporting the toxicity of soluble
768 oligomers rather than amyloid fibrils (Fändrich, 2012; Glabe, 2006). Since LBs are often
769 found in apparently healthy neurons, and degenerating neurons usually lack LBs, some have
770 suggested that the sequestration of polyglucosan into LBs may be a protective mechanism in
771 neuronal cells (Ganesh et al., 2002; Machado-Salas et al., 2012). *Corpora amylacea*, which
772 appear with aging and various neurological conditions, are also considered a protective
773 response to age-related or pathological degeneration (Rohn, 2015). It has been suggested that
774 the *corpora amylacea* are a repository for hazardous cellular waste that can be cleared by the
775 immune system (Augé, Duran, Guinovart, Pelegrí, & Vilaplana, 2018). Both LBs and
776 *corpora amylacea* are decorated with ubiquitin and p62, a cargo receptor for ubiquitinated
777 proteins that has important roles in autophagy and cellular waste disposal (Augé, Duran, et
778 al., 2018; Criado et al., 2012). Misfolded proteins aggregates are also rich in ubiquitin and
779 p62 (Donaldson et al., 2003). Active cellular sequestration of misfolded proteins has been
780 shown to enhance their response to stress (Escusa-Toret, Vonk, & Frydman, 2013). Also,
781 conversion of low molecular weight amyloid oligomers to high molecular weight aggregates
782 reduces their toxicity within cells (Cohen, Bieschke, Perciavalle, Kelly, & Dillin, 2006). It is

possible that when polyglucosan accumulates, cells activate autophagic pathways to sequester the potentially toxic species into compact bodies, analogous to the sequestration of toxic misfolded proteins and amyloid.

While PGB formation may be a cellular adaptation mechanism, data from multiple diseases indicate that polyglucosan accumulation is pathogenic. Genetic ablation of glycogen synthase in the brain rescues the neurological phenotype in LD mouse models, and overexpression of glycogen synthase induces polyglucosan accumulation and neurodegeneration in WT flies and mice (Duran, Gruart, Garcia-Rocha, Delgado-Garcia, & Guinovart, 2014; Duran et al., 2012). Similarly, inhibition of glycogen synthase eliminates PGBs and reverses neurotoxicity in a cell model of Adult Polyglucosan Body Disorder (Kakhlon et al., 2013). Glycogen synthase ablation in WT mice also eliminates the formation of *corpora amylacea* with aging, and a reduction in glycogen synthesis eliminates polyglucosan deposits and increases lifespan in *Drosophila* (Sinadinos et al., 2014). Further investigation will be necessary to understand how polyglucosan is sequestered as PGBs *in vivo*, why various forms of polyglucosan are pathological, and what can be done to alleviate their toxicity.

5. Conclusions

In this study, we defined the architecture of LBs, the hallmark PGBs of a fatal childhood epilepsy. The hypothesis that LBs contain starch-like properties was confirmed: LBs possess B-type crystallinity like starch, but they lack a lamellar arrangement and contain randomly arrayed helical chains. We show that multiple treatments drastically alter the appearance of LBs, breaking them into particles and/or networks. Like starch, the polyglucosan of LBs undergoes retrogradation, acquiring crystallinity spontaneously over time. We propose a model of LB hierarchical structure and formation based on these results, hypothesizing that *in*

vivo, aggregation into networks occurs spontaneously, while sequestration into compact LBs is assisted by proteins. Future work will be required to define how LBs are sequestered, why morphology differs between tissues, and whether the polyglucosan particles, networks or intact PGBs are most toxic. We also present clear nomenclature for describing the various levels of LB structure. These results are also relevant to understanding PGBs found in other diseases and pathologies.

Author Contributions

MKB, AR and AU purified LBs, performed light microscopy experiments and analyzed data. JLP performed SAXS, WAXS, and TEM experiments and analyzed data. MAS performed SEC and analyzed data. MKB, JLP, MAS and MSG wrote the paper.

Conflict of Interest Statement

All authors declare no competing interests.

Acknowledgements

This work was supported by the National Institutes of Health [R01 NS070899 to M.S.G., P01 NS097197 to M.S.G., R35 NS116824 to M.S.G., F31 NS093892 to M.K.B], an Epilepsy Foundation New Therapy Commercialization Grant to M.S.G., an award from the Mizutani Foundation for Glycoscience to M.S.G., and the Glyco@Alps program [ANR-15-IDEX-02]. M.K.B. has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement [No. 754510M]. M.A.S. is supported by a Mater Research McGuckin Early Career Fellowship, the University of Queensland's Amplify Initiative and Mater Foundation. We acknowledge the NanoBio-ICMG Platform (FR 2607, Grenoble, France) for granting access to the Electron Microscopy

833 facility and Ziyi Wang for extracting the rat muscle glycogen, which was used as a reference
834 sample for SEC. We also thank Xinle Tan for his technical assistance with SEC experiments,
835 Robert Gilbert for providing access to SEC equipment, Dr. Carole Moncman, Dr. Thomas
836 Wilkop and the UK Light Microscopy Core for technical support, and all members of the
837 Gentry lab and Dr. Craig Vander Kooi for constructive discussions.

838

839 **Supplementary Files:**

840 **Figure S1.** Additional confocal images of starch and LBs.

841 **Figure S2.** Schematic diagram of SAXS and WAXS experimental setup and theory.

842 **Figure S3.** 2D SAXS and WAXS diffraction patterns.

843 **Figure S4.** Additional TEM image of heated SmLBs.

844

References

- Akman, H. O., Oldfors, A., & DiMauro, S. (2015). *Glycogen Storage Diseases of Muscle*. In B. T. Darras, H. R. Jones, M. M. Ryan & D. C. De Vivo (Eds.), *Neuromuscular Disorders of Infancy, Childhood, and Adolescence: A Clinician's Approach* (pp. 735-760): Academic Press
- Archibald, A. R., Fleming, I. D., Liddle, A. M., Manners, D. J., Mercer, G. A., & Wright, A. (1961). 232. α -1, 4-Glucosans. Part XI. The absorption spectra of glycogen–and amylopectin–iodine complexes. *Journal of the Chemical Society (Resumed)*, 1183-1190.
- Augé, E., Duran, J., Guinovart, J. J., Pelegrí, C., & Vilaplana, J. (2018). Exploring the elusive composition of corpora amylacea of human brain. *Scientific reports*, 8(1), 13525.
- Augé, E., Pelegrí, C., Manich, G., Cabezón, I., Guinovart, J. J., Duran, J., & Vilaplana, J. (2018). Astrocytes and neurons produce distinct types of polyglucosan bodies in Lafora Disease. *Glia*, in press.
- Bahaji, A., Li, J., Ovecka, M., Ezquer, I., Muñoz, F. J., Baroja-Fernández, E., . . . Hidalgo, M. (2011). Arabidopsis thaliana mutants lacking ADP-glucose pyrophosphorylase accumulate starch and wild-type ADP-glucose content: further evidence for the occurrence of important sources, other than ADP-glucose pyrophosphorylase, of ADP-glucose linked to leaf starch biosynthesis. *Plant and cell physiology*, 52(7), 1162-1176.
- Berard-Badier, M., Pellissier, J. F., Gambarelli, D., de Barsy, T., Roger, J., & Toga, M. (1980). The retina in Lafora disease: light and electron microscopy. *Albrecht Von Graefes Arch Klin Exp Ophthalmol*, 212(3-4), 285-294.
- Bertoft, E. (2017). Understanding Starch Structure: Recent Progress. *Agronomy*, 7(3).
- Blazek, J., & Gilbert, E. P. (2011). Application of small-angle X-ray and neutron scattering techniques to the characterisation of starch structure: A review. *Carbohydrate Polymers*, 85(2), 281-293.
- Brewer, M. K., & Gentry, M. S. (2019). Brain Glycogen Structure and Its Associated Proteins: Past, Present and Future. *Adv Neurobiol*, 23, 17-81.
- Brewer, M. K., Uittenbogaard, A., Austin, G. L., Segvich, D. M., DePaoli-Roach, A., Roach, P. J., . . . Gentry, M. S. (2019). Targeting Pathogenic Lafora Bodies in Lafora Disease Using an Antibody-Enzyme Fusion. *Cell Metab*.
- Buléon, A., Bizot, H., Delage, M. M., & Pontoire, B. (1987). Comparison of X-ray diffraction patterns and sorption properties of the hydrolyzed starches of potato, wrinkled and smooth pea, broad bean and wheat. *Carbohydrate Polymers*, 7(6), 461-482.
- Cafferty, M. S., Lovelace, R. E., Hays, A. P., Servidei, S., Dimauro, S., & Rowland, L. P. (1991). Polyglucosan body disease. *Muscle Nerve*, 14(2), 102-107.

883 Cai, L., & Shi, Y.-C. (2013). Self-assembly of short linear chains to A-and B-type starch
884 spherulites and their enzymatic digestibility. *Journal of agricultural and food*
885 *chemistry*, 61(45), 10787-10797.

886 Cameron, R. E., & Donald, A. M. (1991). *Small-angle X-ray scattering and differential*
887 *scanning calorimetry from starch and retrograded starch*. In *Food polymers, gels and*
888 *colloids* (pp. 301-309): The Royal Society of Chemistry Cambridge

889 Cameron, R. E., & Donald, A. M. (1992). A small-angle X-ray scattering study of the
890 annealing and gelatinization of starch. *Polymer*, 33(12), 2628-2635.

891 Cavanagh, J. B. (1999). Corpora-amylacea and the family of polyglucosan diseases. *Brain*
892 *Res Brain Res Rev*, 29(2-3), 265-295.

893 Cleven, R., Van den Berg, C., & Van Der Plas, L. (1978). Crystal structure of hydrated potato
894 starch. *Starch - Stärke*, 30(7), 223-228.

895 Cohen, E., Bieschke, J., Perciavalle, R. M., Kelly, J. W., & Dillin, A. (2006). Opposing
896 activities protect against age-onset proteotoxicity. *Science*, 313(5793), 1604-1610.

897 Criado, O., Aguado, C., Gayarre, J., Duran-Trio, L., Garcia-Cabrero, A. M., Vernia, S., . . .
898 Rodriguez de Cordoba, S. (2012). Lafora bodies and neurological defects in malin-
899 deficient mice correlate with impaired autophagy. *Hum Mol Genet*, 21(7), 1521-1533.

900 DePaoli-Roach, A. A., Contreras, C. J., Segvich, D. M., Heiss, C., Ishihara, M., Azadi, P., &
901 Roach, P. J. (2014). Glycogen phosphomonoester distribution in mouse models of the
902 progressive myoclonic epilepsy, Lafora disease. *J Biol Chem*.

903 DePaoli-Roach, A. A., Contreras, C. J., Segvich, D. M., Heiss, C., Ishihara, M., Azadi, P., &
904 Roach, P. J. (2015). Glycogen phosphomonoester distribution in mouse models of the
905 progressive myoclonic epilepsy, Lafora disease. *Journal of Biological Chemistry*,
906 290(2), 841-850.

907 DePaoli-Roach, A. A., Segvich, D. M., Meyer, C. M., Rahimi, Y., Worby, C. A., Gentry, M.
908 S., & Roach, P. J. (2012). Laforin and malin knockout mice have normal glucose
909 disposal and insulin sensitivity. *Hum Mol Genet*, 21(7), 1604-1610.

910 DePaoli-Roach, A. A., Tagliabracci, V. S., Segvich, D. M., Meyer, C. M., Irimia, J. M., &
911 Roach, P. J. (2010). Genetic depletion of the malin E3 ubiquitin ligase in mice leads
912 to lafora bodies and the accumulation of insoluble laforin. *J Biol Chem*, 285(33),
913 25372-25381.

914 Donald, A. K., Kato, K. L., Perry, P. A., & Waigh, T. A. (2001). Scattering Studies of the
915 Internal Structure of Starch Granules. *Starch*, 53(10), 504-512.

916 Donaldson, K. M., Li, W., Ching, K. A., Batalov, S., Tsai, C.-C., & Joazeiro, C. A. (2003).
917 Ubiquitin-mediated sequestration of normal cellular proteins into polyglutamine
918 aggregates. *Proceedings of the National Academy of Sciences*, 100(15), 8892-8897.

919 Duran, J., Gruart, A., Garcia-Rocha, M., Delgado-Garcia, J. M., & Guinovart, J. J. (2014).
920 Glycogen accumulation underlies neurodegeneration and autophagy impairment in
921 Lafora disease. *Hum Mol Genet*, 23(12), 3147-3156.

- 922 Duran, J., & Guinovart, J. J. (2015). Brain glycogen in health and disease. *Mol Aspects Med*,
923 46, 70-77.
- 924 Duran, J., Tevy, M. F., Garcia-Rocha, M., Calbo, J., Milan, M., & Guinovart, J. J. (2012).
925 Deleterious effects of neuronal accumulation of glycogen in flies and mice. *EMBO*
926 *Mol Med*, 4(8), 719-729.
- 927 Emanuelle, S., Brewer, M. K., Meekins, D. A., & Gentry, M. S. (2016). Unique carbohydrate
928 binding platforms employed by the glucan phosphatases. *Cell Mol Life Sci*, 73(14),
929 2765-2778.
- 930 Escusa-Toret, S., Vonk, W. I., & Frydman, J. (2013). Spatial sequestration of misfolded
931 proteins by a dynamic chaperone pathway enhances cellular fitness during stress.
932 *Nature cell biology*, 15(10), 1231.
- 933 Fändrich, M. (2012). Oligomeric intermediates in amyloid formation: structure determination
934 and mechanisms of toxicity. *J Mol Biol*, 421(4-5), 427-440.
- 935 Ganesh, S., Delgado-Escueta, A. V., Sakamoto, T., Avila, M. R., Machado-Salas, J., Hoshii,
936 Y., . . . Yamakawa, K. (2002). Targeted disruption of the Epm2a gene causes
937 formation of Lafora inclusion bodies, neurodegeneration, ataxia, myoclonus epilepsy
938 and impaired behavioral response in mice. *Hum Mol Genet*, 11(11), 1251-1262.
- 939 Gentry, M. S., Afawi, Z., Armstrong, D. D., Delgado-Escueta, A. V., Goldberg, Y. P.,
940 Grossman, T. R., . . . Serratosa, J. M. (2020). The 5th International Lafora Epilepsy
941 Workshop: Basic science elucidating therapeutic options and preparing for therapies
942 in the clinic. *Epilepsy Behav*(In Press).
- 943 Gentry, M. S., Dixon, J. E., & Worby, C. A. (2009). Lafora disease: insights into
944 neurodegeneration from plant metabolism. *Trends Biochem Sci*, 34(12), 628-639.
- 945 Gentry, M. S., Downen, R. H., 3rd, Worby, C. A., Mattoo, S., Ecker, J. R., & Dixon, J. E.
946 (2007). The phosphatase laforin crosses evolutionary boundaries and links
947 carbohydrate metabolism to neuronal disease. *J Cell Biol*, 178(3), 477-488.
- 948 Gentry, M. S., Guinovart, J. J., Minassian, B. A., Roach, P. J., & Serratosa, J. M. (2018).
949 Lafora disease offers a unique window into neuronal glycogen metabolism. *J Biol*
950 *Chem*, 293(19), 7117-7125.
- 951 Gentry, M. S., Worby, C. A., & Dixon, J. E. (2005). Insights into Lafora disease: malin is an
952 E3 ubiquitin ligase that ubiquitinates and promotes the degradation of laforin. *Proc*
953 *Natl Acad Sci U S A*, 102(24), 8501-8506.
- 954 Gerard, C., Planchot, V., Colonna, P., & Bertoft, E. (2000). Relationship between branching
955 density and crystalline structure of A- and B-type maize mutant starches. *Carbohydr*
956 *Res*, 326(2), 130-144.
- 957 Gidley, M. J., & Bulpin, P. V. (1987). Crystallisation of malto-oligosaccharides as models of
958 the crystalline forms of starch: minimum chain-length requirement for the formation
959 of double helices. *Carbohydrate Research*, 161(2), 291-300.

- 960 Glabe, C. G. (2006). Common mechanisms of amyloid oligomer pathogenesis in
961 degenerative disease. *Neurobiology of aging*, 27(4), 570-575.
- 962 Goldstein, A., Annor, G., Putaux, J.-L., Hebelstrup, K. H., Blennow, A., & Bertoft, E. (2016).
963 Impact of full range of amylose contents on the architecture of starch granules.
964 *International journal of biological macromolecules*, 89, 305-318.
- 965 Good, C. A. K., H.; Somogyi, M. (1933). The determination of glycogen. *J. Biol. Chem.*, 100,
966 485-491.
- 967 Herrick, M. K., Twiss, J. L., Vladutiu, G. D., Glasscock, G. F., & Horoupian, D. S. (1994).
968 Concomitant branching enzyme and phosphorylase deficiencies. An unusual
969 glycogenosis with extensive neuronal polyglucosan storage. *J Neuropathol Exp*
970 *Neurol*, 53(3), 239-246.
- 971 Imberty, A., & Perez, S. (1988). A revisit to the three - dimensional structure of B - type
972 starch. *Biopolymers: Original Research on Biomolecules*, 27(8), 1205-1221.
- 973 Irimia, J. M., Tagliabracci, V. S., Meyer, C. M., Segvich, D. M., DePaoli-Roach, A. A., &
974 Roach, P. J. (2015). Muscle glycogen remodeling and glycogen phosphate
975 metabolism following exhaustive exercise of wild type and laforin knockout mice. *J*
976 *Biol Chem*.
- 977 Ishihara, T., Yokota, T., Yamashita, Y., Takahashi, M., Kawano, H., Uchino, F., . . . Yamada,
978 M. (1987). Comparative study of the intracytoplasmic inclusions in Lafora disease
979 and type IV glycogenosis by electron microscopy. *Acta Pathol Jpn*, 37(10), 1591-
980 1601.
- 981 Jacobs, H., Eerlingen, R. C., Rouseu, N., Colonna, P., & Delcour, J. A. (1998). Acid
982 hydrolysis of native and annealed wheat, potato and pea starches—DSC melting
983 features and chain length distributions of lintnerised starches. *Carbohydrate*
984 *Research*, 308(3-4), 359-371.
- 985 Jane, J. I., Chen, Y., Lee, L., McPherson, A., Wong, K., Radosavljevic, M., & Kasemsuwan,
986 T. (1999). Effects of amylopectin branch chain length and amylose content on the
987 gelatinization and pasting properties of starch. *Cereal chemistry*, 76(5), 629-637.
- 988 Kakhlon, O., Glickstein, H., Feinstein, N., Liu, Y., Baba, O., Terashima, T., . . . Lossos, A.
989 (2013). Polyglucosan neurotoxicity caused by glycogen branching enzyme deficiency
990 can be reversed by inhibition of glycogen synthase. *J Neurochem*, 127(1), 101-113.
- 991 Kerly, M. (1930). The solubility of glycogen. *Biochemical Journal*, 24(1), 67.
- 992 Kyle, R. A. (2001). Amyloidosis: a convoluted story. *Br J Haematol*, 114(3), 529-538.
- 993 Lafora, G. R. (1911). Über des Vorkommen amyloider Körperchen im innern der
994 Ganglienzellen. *Virchows Arch. f. Path. Anat.*, 205, 295.
- 995 Lourdin, D., Putaux, J.-L., Potocki-Véronèse, G., Chevigny, C., Rolland-Sabaté, A., &
996 Buléon, A. (2015). *Crystalline Structure in Starch*. In Y. Nakamura (Ed.), *Starch:*
997 *Metabolism and Structure* (pp. 61-90). Tokyo: Springer Japan

998 Machado-Salas, J., Avila-Costa, M. R., Guevara, P., Guevara, J., Duron, R. M., Bai, D., . . .
999 Delgado-Escueta, A. V. (2012). Ontogeny of Lafora bodies and neurocytoskeleton
1000 changes in Laforin-deficient mice. *Exp Neurol*, 236(1), 131-140.

1001 Majzoobi, M., Seifzadeh, N., Farahnaky, A., & Mesbahi, G. (2015). Effects of sonication on
1002 physical properties of native and cross - linked wheat starches. *Journal of Texture*
1003 *Studies*, 46(2), 105-112.

1004 Melendez-Hevia, E., Waddell, T. G., & Shelton, E. D. (1993). Optimization of molecular
1005 design in the evolution of metabolism: the glycogen molecule. *Biochem J*, 295 (Pt 2),
1006 477-483.

1007 Michen, B., Geers, C., Vanhecke, D., Endes, C., Rothen-Rutishauser, B., Balog, S., & Petri-
1008 Fink, A. (2015). Avoiding drying-artifacts in transmission electron microscopy:
1009 Characterizing the size and colloidal state of nanoparticles. *Scientific reports*, 5, 9793.

1010 Minassian, B. A. (2001). Lafora's disease: towards a clinical, pathologic, and molecular
1011 synthesis. *Pediatr Neurol*, 25(1), 21-29.

1012 Nakamura, Y. (2015). Starch: Metabolism and Structure. Akita, Japan: Springer.

1013 Nitschke, F., Sullivan, M. A., Wang, P., Zhao, X., Chown, E. E., Perri, A. M., . . . Minassian,
1014 B. A. (2017). Abnormal glycogen chain length pattern, not hyperphosphorylation, is
1015 critical in Lafora disease. 9(7), 906-917.

1016 Nitschke, F., Wang, P., Schmieder, P., Girard, J. M., Awrey, D. E., Wang, T., . . . Minassian,
1017 B. A. (2013). Hyperphosphorylation of glucosyl c6 carbons and altered structure of
1018 glycogen in the neurodegenerative epilepsy lafora disease. *Cell Metab*, 17(5), 756-
1019 767.

1020 Ovecka, M., Bahaji, A., Munoz, F. J., Almagro, G., Ezquer, I., Baroja-Fernandez, E., . . .
1021 Pozueta-Romero, J. (2012). A sensitive method for confocal fluorescence microscopic
1022 visualization of starch granules in iodine stained samples. *Plant Signal Behav*, 7(9),
1023 1146-1150.

1024 Perera, A., Meda, V., & Tyler, R. T. (2010). Resistant starch: A review of analytical
1025 protocols for determining resistant starch and of factors affecting the resistant starch
1026 content of foods. *Food Research International*, 43(8), 1959-1974.

1027 Pflüger, E. (1909). Meine Methode der quantitativen Analyse des Glykogenes und die
1028 Arteigenthümlichkeit der Substanzen des Thierleibes. *Archiv für die gesamte*
1029 *Physiologie des Menschen und der Tiere*, 129(6-7), 362-378.

1030 Popov, D., Buléon, A., Burghammer, M., Chanzy, H., Montesanti, N., Putaux, J.-L., . . .
1031 Riekel, C. (2009). Crystal structure of A-amylose: A revisit from synchrotron
1032 microdiffraction analysis of single crystals. *Macromolecules*, 42(4), 1167-1174.

1033 Putaux, J.-L., Buleon, A., & Chanzy, H. (2000). Network formation in dilute amylose and
1034 amylopectin studied by TEM. *Macromolecules*, 33(17), 6416-6422.

- 1035 Putaux, J.-L., Molina-Boisseau, S., Momaour, T., & Dufresne, A. (2003). Platelet nanocrystals
1036 resulting from the disruption of waxy maize starch granules by acid hydrolysis.
1037 *Biomacromolecules*, 4(5), 1198-1202.
- 1038 Putaux, J.-L., Potocki-Véronese, G., Remaud-Simeon, M., & Buleon, A. (2006). α -D-Glucan-
1039 based dendritic nanoparticles prepared by in vitro enzymatic chain extension of
1040 glycogen. *Biomacromolecules*, 7(6), 1720-1728.
- 1041 Qiao, D., Zhang, B., Huang, J., Xie, F., Wang, D. K., Jiang, F., . . . Zhu, J. (2017). Hydration-
1042 induced crystalline transformation of starch polymer under ambient conditions.
1043 *International journal of biological macromolecules*, 103, 152-157.
- 1044 Raben, N., Danon, M., Lu, N., Lee, E., Shliselfeld, L., Skurat, A. V., . . . Plotz, P. (2001).
1045 Surprises of genetic engineering: A possible model of polyglucosan body disease.
1046 *Neurology*, 56(12), 1739-1745.
- 1047 Raththagala, M., Brewer, M. K., Parker, M. W., Sherwood, A. R., Wong, B. K., Hsu, S., . . .
1048 Gentry, M. S. (2015). Structural mechanism of laforin function in glycogen
1049 dephosphorylation and lafora disease. *Mol Cell*, 57(2), 261-272.
- 1050 Ratnayake, W. S., & Jackson, D. S. (2006). Gelatinization and solubility of corn starch
1051 during heating in excess water: new insights. *Journal of Agricultural and Food*
1052 *Chemistry*, 54(10), 3712-3716.
- 1053 Ratnayake, W. S., & Jackson, D. S. (2009). Starch gelatinization. *Adv Food Nutr Res*, 55,
1054 221-268.
- 1055 Reed Jr, G. B., Dixon, J. F., Neustein, J. B., Donnell, G. N., & Landing, B. H. (1968). Type
1056 IV glycogenosis. Patient with absence of a branching enzyme alpha-1, 4-glucan:
1057 alpha-1, 4-glucan 6-glycosyl transferase. *Laboratory investigation; a journal of*
1058 *technical methods and pathology*, 19(5), 546.
- 1059 Revel, J. P., Napolitano, L., & Fawcett, D. W. (1960). Identification of glycogen in electron
1060 micrographs of thin tissue sections. *J Cell Biol*, 8(3), 575-589.
- 1061 Ritte, G., Heydenreich, M., Mahlow, S., Haebel, S., Kotting, O., & Steup, M. (2006).
1062 Phosphorylation of C6- and C3-positions of glucosyl residues in starch is catalysed by
1063 distinct dikinases. *FEBS Lett*, 580(20), 4872-4876.
- 1064 Roach, P. J. (2002). Glycogen and its Metabolism. *Current Molecular Medicine*, 2, 101-120.
- 1065 Roach, P. J., Depaoli-Roach, A. A., Hurley, T. D., & Tagliabracci, V. S. (2012). Glycogen
1066 and its metabolism: some new developments and old themes. *Biochem J*, 441(3), 763-
1067 787.
- 1068 Rohn, T. T. (2015). Corpora Amylacea in Neurodegenerative Diseases: Cause or Effect? *Int J*
1069 *Neurol Neurother*, 2(3).
- 1070 Rubio-Villena, C., Viana, R., Bonet, J., Garcia-Gimeno, M. A., Casado, M., Heredia, M., &
1071 Sanz, P. (2018). Astrocytes: new players in progressive myoclonus epilepsy of Lafora
1072 type. *Hum Mol Genet*.

- 1073 Rundle, R. E., Foster, J. F., & Baldwin, R. R. (1944). On the nature of the starch—iodine
1074 complex. *Journal of the American Chemical Society*, 66(12), 2116-2120.
- 1075 Ryu, J. H., Drain, J., Kim, J. H., McGee, S., Gray-Weale, A., Waddington, L., . . . Stapleton,
1076 D. (2009). Comparative structural analyses of purified glycogen particles from rat
1077 liver, human skeletal muscle and commercial preparations. *Int J Biol Macromol*,
1078 45(5), 478-482.
- 1079 Sakai, M., Austin, J., Witmer, F., & Trueb, L. (1969). Studies of corpora amylacea. I.
1080 Isolation and preliminary characterization by chemical and histochemical techniques.
1081 *Arch Neurol*, 21(5), 526-544.
- 1082 Sakai, M., Austin, J., Witmer, F., & Trueb, L. (1970). Studies in myoclonus epilepsy (Lafora
1083 body form). II. Polyglucosans in the systemic deposits of myoclonus epilepsy and in
1084 corpora amylacea. *Neurology*, 20(2), 160-176.
- 1085 Sinadinos, C., Valles-Ortega, J., Boulan, L., Solsona, E., Tevy, M. F., Marquez, M., . . .
1086 Guinovart, J. J. (2014). Neuronal glycogen synthesis contributes to physiological
1087 aging. *Aging Cell*, 13(5), 935-945.
- 1088 Sipe, J. D., & Cohen, A. S. (2000). Review: history of the amyloid fibril. *J Struct Biol*, 130(2-
1089 3), 88-98.
- 1090 Srichuwong, S., Isono, N., Mishima, T., & Hisamatsu, M. (2005). Structure of lintnerized
1091 starch is related to X-ray diffraction pattern and susceptibility to acid and enzyme
1092 hydrolysis of starch granules. *International journal of biological macromolecules*,
1093 37(3), 115-121.
- 1094 Stetten, M. R., Katzen, H. M., & Stetten, D. (1958). A comparison of the glycogens isolated
1095 by acid and alkaline procedures. *Journal of Biological Chemistry*, 232(1), 475-488.
- 1096 Sullivan, M. A., Nitschke, S., Skwara, E. P., Wang, P., Zhao, X., Pan, X. S., . . . Lee, J. P.
1097 (2019). Skeletal Muscle Glycogen Chain Length Correlates with Insolubility in
1098 Mouse Models of Polyglucosan-Associated Neurodegenerative Diseases. *Cell reports*,
1099 27(5), 1334-1344. e1336.
- 1100 Sullivan, M. A., Nitschke, S., Steup, M., Minassian, B. A., & Nitschke, F. (2017).
1101 Pathogenesis of Lafora Disease: Transition of Soluble Glycogen to Insoluble
1102 Polyglucosan. *Int J Mol Sci*, 18(8).
- 1103 Sullivan, M. A., Powell, P. O., Witt, T., Vilaplana, F., Roura, E., & Gilbert, R. G. (2014).
1104 Improving size-exclusion chromatography separation for glycogen. *Journal of*
1105 *Chromatography A*, 1332, 21-29.
- 1106 Sullivan, M. A., Vilaplana, F., Cave, R. A., Stapleton, D., Gray-Weale, A. A., & Gilbert, R.
1107 G. (2010). Nature of α and β particles in glycogen using molecular size distributions.
1108 *Biomacromolecules*, 11(4), 1094-1100.
- 1109 Svegmarm, K., Helmersson, K., Nilsson, G., Nilsson, P. O., Andersson, R., & Svensson, E.
1110 (2002). Comparison of potato amylopectin starches and potato starches—influence of
1111 year and variety. *Carbohydrate Polymers*, 47(4), 331-340.

- 1112 Swanson, M. A. (1948). Studies on the structure of polysaccharides; relation of the iodine
1113 color to the structure. *J Biol Chem*, 172(2), 825-837.
- 1114 Tagliabracci, V. S., Girard, J. M., Segvich, D., Meyer, C., Turnbull, J., Zhao, X., . . . Roach,
1115 P. J. (2008). Abnormal metabolism of glycogen phosphate as a cause for Lafora
1116 disease. *J Biol Chem*, 283(49), 33816-33825.
- 1117 Tagliabracci, V. S., Heiss, C., Karthik, C., Contreras, C. J., Glushka, J., Ishihara, M., . . .
1118 Roach, P. J. (2011). Phosphate incorporation during glycogen synthesis and Lafora
1119 disease. *Cell Metab*, 13(3), 274-282.
- 1120 Tester, R. F., Karkalas, J., & Qi, X. (2004). Starch—composition, fine structure and
1121 architecture. *Journal of Cereal Science*, 39(2), 151-165.
- 1122 Thys, R. C. S., Westfahl Jr, H., Noreña, C. P. Z., Marczak, L. D. F., Silveira, N. P., &
1123 Cardoso, M. B. (2008). Effect of the alkaline treatment on the ultrastructure of C-type
1124 starch granules. *Biomacromolecules*, 9(7), 1894-1901.
- 1125 Tiberia, E., Turnbull, J., Wang, T., Ruggieri, A., Zhao, X. C., Pencea, N., . . . Minassian, B.
1126 A. (2012). Increased laforin and laforin binding to glycogen underlie Lafora body
1127 formation in malin-deficient Lafora disease. *J Biol Chem*, 287(30), 25650-25659.
- 1128 Valles-Ortega, J., Duran, J., Garcia-Rocha, M., Bosch, C., Saez, I., Pujadas, L., . . .
1129 Guinovart, J. J. (2011). Neurodegeneration and functional impairments associated
1130 with glycogen synthase accumulation in a mouse model of Lafora disease. *EMBO
1131 Mol Med*, 3(11), 667-681.
- 1132 Van Heycop Ten Ham, M. W. (1975). *Lafora disease, a form of progressive myoclonus
1133 epilepsy*. In P. J. Vinken & G. W. Bruyn (Eds.), *Handb Clin Neurol* (pp. 382-422).
1134 Holland, Amsterdam: North Holland Publishing Company
- 1135 Virchow, R. (1854). Zur Cellulose-Frage. *Virchows Arch.*, 6(3), 416-426.
- 1136 Wang, S., Luo, H., Zhang, J., Zhang, Y., He, Z., & Wang, S. (2014). Alkali-induced changes
1137 in functional properties and in vitro digestibility of wheat starch: the role of surface
1138 proteins and lipids. *Journal of agricultural and food chemistry*, 62(16), 3636-3643.
- 1139 Wikman, J., Blennow, A., & Bertoft, E. (2013). Effect of amylose deposition on potato tuber
1140 starch granule architecture and dynamics as studied by lintnerization. *Biopolymers*,
1141 99(1), 73-83.
- 1142 Wikman, J., Blennow, A., Buleon, A., Putaux, J. L., Perez, S., Seetharaman, K., & Bertoft, E.
1143 (2014). Influence of amylopectin structure and degree of phosphorylation on the
1144 molecular composition of potato starch lintners. *Biopolymers*, 101(3), 257-271.
- 1145 Worby, C. A., Gentry, M. S., & Dixon, J. E. (2006). Laforin: A dual specificity phosphatase
1146 that dephosphorylates complex carbohydrates. *J. Biol. Chem.*, 281(41), 30412-30418.
- 1147 Yokoi, S., Austin, J., Witmer, F., & Sakai, M. (1968). Studies in myoclonus epilepsy (Lafora
1148 body form). I. Isolation and preliminary characterization of Lafora bodies in two
1149 cases. *Arch Neurol*, 19(1), 15-33.

1150 Young, L. E., Brizzee, C. O., Macedo, J. K., Murphy, R. D., Contreras, C. J., DePaoli-Roach,
1151 A. A., . . . Sun, R. C. (2019). Accurate and sensitive quantitation of glucose and
1152 glucose phosphates derived from storage carbohydrates by mass spectrometry.
1153 *Carbohydrate Polymers*, 115651.

Supplementary data

[Click here to download Supplementary data: Supplemental 3.docx](#)

MKB, AR and AU purified LBs, performed light microscopy experiments and analyzed data.

JLP performed SAXS, WAXS, and TEM experiments and analyzed data. MAS performed SEC and analyzed data. MKB, JLP, MAS and MSG wrote the paper.